UPDATE - October 9, 2025:
The CAA Research Program at MGH is actively enrolling CAA patients for cAPPricorn-1! If you are interested in participating, you can reach out to the study coordinator at 617-724-2829, or reach out via email at mghcappricorn1@mgb.org.
Please note that enrollment will close in early 2026, so interested participants are encouraged to reach out soon.
Additional information regarding the trial can be found here: https://clinicaltrials.gov/study/NCT06393712
If you would like to kept apprised of this and other research opportunities for patients with CAA, please consider joining the CAA Research Recruitment Registry (“CAAR3”).
UPDATE - May 21, 2024:
The CAA Research Program at MGH is excited to announce an upcoming treatment trial for patients with CAA. The trial’s short name is cAPPricorn-1 and the study drug being tested is known as “ALN-APP”. cAPPricorn-1 is sponsored by Alnylam Pharmaceuticals and is expected to launch at MGH in the fall of 2024. Additional information may be found at https://clinicaltrials.gov/study/NCT06393712.
We will share updates and further information about the study’s eligibility criteria and procedures as trial start-up progresses.
If you would like to kept apprised of this and other research opportunities for patients with CAA, please consider joining the CAA Research Recruitment Registry (“CAAR3”).
Ongoing research goals in CAA:
To develop improved diagnostic techniques for detecting CAA
To predict which patients with CAA are at risk for stroke recurrences after they recover from their first stroke
To identify treatments that can substantially lower the risk for stroke recurrence in CAA